CAS: 911116-16-0; 3,3,3-Trifluoropropyl Methanesulfonate
该化合物是一种有机液化合物,其特点是,一个三氟丙基化合物组附于甲烷硫酸混合物,该化合物一般是淡黄色液体的无色物质,以其反应性而著称,特别是有机合成中的一种电益性试剂;三氟丙基化合物组具有独特的特性,如增加脂质和热稳定性,使其在各种应用中有用,包括药物和农用化学品;甲烷硫酸化合物功能组有助于其作为核循环替代反应中的离子组发挥作用的能力;此外,由于氟原子的存在,该化合物可能表现出不同的物理和化学特性,例如与非氟化类相比,温度和熔点发生变化;在处理该物质时,安全考虑十分重要,因为它可能构成健康风险,包括对皮肤和眼睛的刺激,以及潜在的环境影响;应当遵循适当的储存和处理程序来减轻这些风险.
- 英文名称3,3,3-Trifluoropropyl Methanesulfonate
- 中文名称3,3,3-三氟丙基甲磺酸酯
- IUPAC名称3,3,3-trifluoropropyl methanesulfonate
- 其它别名3,3,3-Trifluoropropyl Methansulfonate; 1-Propanol, 3,3,3-Trifluoro-, Methanesulfonate; 1-Propanol, 3,3,3-Trifluoro-, 1-Methanesulfonate
- CAS编号911116-16-0
- MFCD编号:MFCD04973019
- EINECS号:831-822-5
- 分子式:C4H7F3O3S分子量:192.16
- 产品CID: 1945888
- 产品分类有机原料→分子砌块→脂肪链类化合物
相似化合物
120097-63-4 1912-31-8 72486-09-0MSDS等安全信息
欧盟法规
C&L通报上下游产品
3,3,3-Trifluoropropanol methanesulfonyl chloride合成工艺路线路线简述
- 合成目标产物 3,3,3-Trifluoropropyl Methansulfonate 主要起始原料 3,3,3-Trifluoro-1-Propanol And Methanesulfonyl Chloride
- (文献来源)合成步骤主要原料 3,3,3-Trifluoro-1-Propanol 和 Methanesulfonyl Chloride
📜3,3,3-三氟-1-丙醇,甲基磺酰氯 反应生成 3,3,3-三氟丙基甲磺酸酯
参考文献:Medical Use Of Triazine Derivatives
标题:Medical Use Of Triazine Derivatives
摘要:化合物的公式(I),特别是其中r1为可选取代的烷基,芳基烷基或杂环基烷基的化合物,具有作为钠通道阻滞剂或抗叶酸剂的活性.其中一些新颖的化合物,其中r1为芳基烷基或杂环基烷基,已被披露.
海关参考信息
- 2905121000-正丙醇
2904100000-仅含磺基的衍生物及其盐和乙酯
2903399090-其他无环烃卤化衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-7807709-B2
优先权日:2005-03-23
标题 :Organic compounds
发明人：EHRHARDT CLAUS; IRIE OSAMU; LORTHIOIS EDWIGE LILIANE; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; SELLNER HOLGER
权利人:NOVARTIS AG
摘要:The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.
